Kimelman & Baird’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.67M | Hold |
30,656
| – | – | 0.55% | 38 |
|
|
2025
Q4 | $7M | Sell |
30,656
-414
| -1% | -$94.3K | 0.54% | 36 |
|
|
2025
Q3 | $7.19M | Hold |
31,070
| – | – | 0.56% | 35 |
|
|
2025
Q2 | $5.77M | Hold |
31,070
| – | – | 0.47% | 39 |
|
|
2025
Q1 | $6.51M | Hold |
31,070
| – | – | 0.55% | 34 |
|
|
2024
Q4 | $5.52M | Sell |
31,070
-2,696
| -8% | -$496K | 0.44% | 40 |
|
|
2024
Q3 | $6.67M | Hold |
33,766
| – | – | 0.53% | 37 |
|
|
2024
Q2 | $5.79M | Buy |
+33,766
| New | +$5.59M | 0.48% | 40 |
|
|
2021
Q2 | $3.3M | Buy |
+29,289
| New | +$3.3M | 0.29% | 49 |
|
|
2019
Q3 | $2.2M | Sell |
29,014
-20
| -0.1% | -$1.37K | 0.3% | 51 |
|
|
2019
Q2 | $2.11M | Buy |
29,034
+606
| +2% | +$47.6K | 0.29% | 49 |
|
|
2019
Q1 | $2.29M | Hold |
28,428
| – | – | 0.33% | 50 |
|
|
2018
Q4 | $2.62M | Hold |
28,428
| – | – | 0.41% | 47 |
|
|
2018
Q3 | $2.69M | Hold |
28,428
| – | – | 0.34% | 51 |
|
|
2018
Q2 | $2.63M | Buy |
+28,428
| New | +$2.78M | 0.35% | 50 |
|
|
2017
Q4 | $2.75M | Hold |
28,400
| – | – | 0.39% | 49 |
|
|
2017
Q3 | $2.52M | Hold |
28,400
| – | – | 0.38% | 52 |
|
|
2017
Q2 | $2.06M | Sell |
28,400
-100
| -0.4% | -$6.72K | 0.31% | 56 |
|
|
2017
Q1 | $1.86M | Hold |
28,500
| – | – | 0.28% | 53 |
|
|
2016
Q4 | $1.78M | Hold |
28,500
| – | – | 0.3% | 50 |
|
|
2016
Q3 | $1.8M | Hold |
28,500
| – | – | 0.32% | 50 |
|
|
2016
Q2 | $1.76M | Hold |
28,500
| – | – | 0.32% | 51 |
|
|
2016
Q1 | $1.63M | Hold |
28,500
| – | – | 0.3% | 52 |
|
|
2015
Q4 | $1.69M | Buy |
+28,500
| New | +$1.64M | 0.32% | 56 |
|
|
2015
Q2 | $1.92M | Sell |
28,500
-1,902
| -6% | -$124K | 0.33% | 59 |
|
|
2015
Q1 | $1.78M | Hold |
30,402
| – | – | 0.32% | 59 |
|
|
2014
Q4 | $1.99M | Buy |
30,402
+302
| +1% | +$19K | 0.36% | 56 |
|
|
2014
Q3 | $1.74M | Hold |
30,100
| – | – | 0.33% | 61 |
|
|
2014
Q2 | $1.7M | Hold |
30,100
| – | – | 0.3% | 63 |
|
|
2014
Q1 | $1.55M | Hold |
30,100
| – | – | 0.29% | 58 |
|
|
2013
Q4 | $1.59M | Buy |
30,100
+1,600
| +6% | +$78.6K | 0.3% | 60 |
|
|
2013
Q3 | $1.27M | Hold |
28,500
| – | – | 0.25% | 64 |
|
|
2013
Q2 | $1.18M | Buy |
+28,500
| New | +$1.25M | 0.25% | 64 |
|
Other funds holding ABBV
VCM
VPM
Kimelman & Baird's ABBV Position: Q1 2026 in Review
Kimelman & Baird held its AbbVie (ABBV) position steady in Q1 2026 at 30,656 shares worth $6.67M. The position accounts for 0.55% of the portfolio, ranked #38.
Kimelman & Baird first reported a position in ABBV in Q2 2013 and has held it in 33 quarters since. The position peaked at $7.19M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Kimelman & Baird held 30,656 shares of AbbVie worth $6.67M as of Q1 2026.
- Kimelman & Baird left its AbbVie share count unchanged in Q1 2026.
- AbbVie made up 0.55% of Kimelman & Baird's portfolio in Q1 2026, its #38 holding.
- Kimelman & Baird first reported a position in AbbVie in Q2 2013 and has held it in 33 quarters since.
- Kimelman & Baird's AbbVie position peaked at $7.19M in Q3 2025.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Kimelman & Baird's 13F filing for Q1 2026, filed 13 May 2026.